SCHEMBL25811779

SCHEMBL25811779

Cn1c2c(c3cc(C(=O)NCCN4CCC4)ccc31)CCCC2

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
MEN1 O00255 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
RAD52 P43351 1/20 0.51
MAPT P10636 1/20 0.51
ALOX5 P09917 1/20 0.50
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
HTR3A P46098 1/20 0.50
POLB P06746 2/20 0.49
RORC P51449 2/20 0.48
HPGD P15428 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PARP1 P09874 1/20 0.47
GLA P06280 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812597 0.98 KMT2A (0.58) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25815123 0.98 KMT2A (0.61) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25811762 0.97 KMT2A (0.62) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25811754 0.95 KMT2A (0.61) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25813448 0.95 RAD52 (0.59) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25812566 0.93 KMT2A (0.62) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL25811726 0.92 RAD52 (0.59) KMT2AMEN1NPSR1RAD52MAPT
SCHEMBL25936813 0.84 ALOX5 (0.52) KMT2AMEN1MAPTALOX5PTGS1
SCHEMBL25936806 0.83 ALOX5 (0.51) KMT2AMEN1MAPTALOX5PTGS1
SCHEMBL30401813 0.81 RAD52 (0.74) KMT2AMEN1NPSR1RAD52MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885MEN1 3841/4885NPSR1 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.